First published · Last updated
O2-1 Nivolumab + ipilimumab versus chemotherapy in MSI-H/dMMR metastatic colorectal cancer: CheckMate 8HW Asian subgroup analysis
Journal article reporting an Asian subgroup analysis of CheckMate 8HW comparing nivolumab plus ipilimumab versus chemotherapy in MSI-H/dMMR metastatic colorectal cancer. Publisher listed as Elsevier BV with publication date 2025-10-01.
Categories: public-health, science-and-space
Generated scores
Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.
- Confidence
- 4/10
- Geographic reach
- 6/10
- Global importance
- 3/10
- Impact magnitude
- 3/10
- Positivity
- 5/10
- Urgency
- 2/10
Why it matters
This article presents a clinical subgroup comparison of immunotherapy versus chemotherapy for MSI-H/dMMR metastatic colorectal cancer in Asian patients.

